Spyre halts RA program for anti-TL1A candidate after Phase 2 disappointment
Spyre Therapeutics is deprioritizing its anti-TL1A antibody for rheumatoid arthritis after the drug failed to meet the company's threshold for success in a mid-stage trial. The decision casts doubt on the broader potential of the candidate, though the company has not disclosed full results.
Related stories
Bausch + Lomb pushes dry eye therapy to Phase 3 after Phase 2 miss · Drug development
Ebola Vaccine Doses Headed to Congo Amid Fast-Spreading Outbreak · Infectious disease
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data.” Browse more stories.